{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:37:18Z","timestamp":1782193038805,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Iowa State University Summer Scholars Research Program"},{"name":"Ceva Sante Animale"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Angiotensin-converting enzyme inhibitors (ACEI) such as benazepril are commonly prescribed in both humans and dogs with heart disease to mitigate the renin\u2013angiotensin\u2013aldosterone system (RAAS); however, the dose-dependent effects of benazepril on comprehensive RAAS components remain unknown. In this study, nine purpose-bred healthy dogs received three different dosages of oral benazepril (0.125\u00a0mg\/kg, 0.25\u00a0mg\/kg, or 0.5\u00a0mg\/kg) in a randomized crossover design following induction of RAAS activation by consuming a low-sodium diet. Blood samples were collected at serial time intervals after benazepril dosing to measure plasma benazeprilat (active metabolite of benazepril) and serum RAAS biomarkers. Blood pressure and echocardiogram were performed at baseline and after each benazepril administration. Time-weighted averages for RAAS biomarkers for 12\u00a0h post-dose and hemodynamic variables were compared between dosing groups using Wilcoxon rank-sum testing. Compared to the lowest dosage of benazepril (0.125\u00a0mg\/kg), the highest dosage (0.5\u00a0mg\/kg) resulted in lower time-weighted average values of angiotensin (Ang) II (\u2212\u00a038%, P\u2009=\u20090.004), Ang1-5 (\u2212\u00a053%, P\u2009=\u20090.001), ACE-S (surrogate for ACE activity; \u2212\u00a059%, P\u2009=\u20090.0002), and ALT-S (surrogate for alternative RAAS activity; \u2212\u00a022%, P\u2009=\u20090.004), and higher values of AngI (+\u200978%, P\u2009=\u20090.014) and PRA-S (surrogate for plasma renin activity;\u2009+\u200958%, P\u2009=\u20090.040). There were no relevant differences between dosing groups for blood pressure or echocardiographic variables. Knowledge of dose-dependent alterations in biomarkers of the classical and alternative RAAS pathways could help inform clinical trials for dosage optimization in both dogs and humans.<\/jats:p>","DOI":"10.1038\/s41598-023-29771-x","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T07:06:05Z","timestamp":1676963165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dose\u2013response of benazepril on biomarkers of the classical and alternative pathways of the renin\u2013angiotensin\u2013aldosterone system in dogs"],"prefix":"10.1038","volume":"13","author":[{"given":"Samantha","family":"Sotillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Domenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingnan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojtech","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea A.","family":"Iennarella-Servantez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Mochel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"29771_CR1","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJV McMurray","year":"2012","unstructured":"McMurray, J. J. V. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur. Heart J. 33, 1787\u20131847 (2012).","journal-title":"Eur. Heart J."},{"key":"29771_CR2","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/jvim.15488","volume":"33","author":"BW Keene","year":"2019","unstructured":"Keene, B. W. et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J. Vet. Intern. Med. 33, 1127\u20131140 (2019).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1939-1676.1995.tb01075.x","volume":"9","author":"The COVE Study Group","year":"1995","unstructured":"The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the cooperative veterinary enalapril study group. J. Vet. Intern. Med. 9, 243\u2013252 (1995).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S1760-2734(06)70025-X","volume":"1","author":"BENCH (Benazepril in Canine Heart Disease) Study Group","year":"1999","unstructured":"BENCH (Benazepril in Canine Heart Disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J. Vet. Cardiol. 1, 7\u201318 (1999).","journal-title":"J. Vet. Cardiol."},{"key":"29771_CR5","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K Swedberg","year":"1990","unstructured":"Swedberg, K., Eneroth, P., Kjekshus, J. & Wilhelmsen, L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality CONSENSUS trial study group. Circulation 82, 1730\u20131736 (1990).","journal-title":"Circulation"},{"key":"29771_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1053\/euhj.1998.1098","volume":"20","author":"K Swedberg","year":"1999","unstructured":"Swedberg, K., Kjekshus, J. & Snapinn, S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur. Heart J. 20, 136\u2013139 (1999).","journal-title":"Eur. Heart J."},{"key":"29771_CR7","doi-asserted-by":"publisher","first-page":"IV6","DOI":"10.1002\/clc.4960141802","volume":"14","author":"JE Hall","year":"1991","unstructured":"Hall, J. E. Control of blood pressure by the renin-angiotensin-aldosterone system. Clin. Cardiol. 14, IV6-21 (1991).","journal-title":"Clin. Cardiol."},{"key":"29771_CR8","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1172\/JCI108431","volume":"57","author":"L Watkins","year":"1976","unstructured":"Watkins, L. et al. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J. Clin. Investig. 57, 1606\u20131617 (1976).","journal-title":"J. Clin. Investig."},{"key":"29771_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/112_2015_27","volume":"169","author":"J Mochel","year":"2015","unstructured":"Mochel, J. & Danhof, M. Chronobiology and pharmacologic modulation of the renin-andiogensin-aldosterone system in dogs: What have we learned?. Rev. Physiol. Biochem. Pharmacol. 169, 43\u201369 (2015).","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"29771_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","volume":"47","author":"EL Shiffrin","year":"2006","unstructured":"Shiffrin, E. L. Effects of aldosterone on the vasculature. Hypertension 47, 312\u2013318 (2006).","journal-title":"Hypertension"},{"key":"29771_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2174\/157016111796642689","volume":"9","author":"F Waanders","year":"2011","unstructured":"Waanders, F. et al. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. Curr. Vasc. Pharmacol. 9, 594\u2013605 (2011).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"29771_CR12","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1172\/JCI117269","volume":"93","author":"M Young","year":"1994","unstructured":"Young, M., Fullerton, M., Dilley, R. & Funder, J. Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Investig. 93, 2578\u201383 (1994).","journal-title":"J. Clin. Investig."},{"key":"29771_CR13","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.2174\/1381612820666141112160013","volume":"21","author":"M Regulski","year":"2014","unstructured":"Regulski, M. et al. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr. Pharm. Des. 21, 1764\u20131775 (2014).","journal-title":"Curr. Pharm. Des."},{"key":"29771_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1365-2885.2004.00601.x","volume":"27","author":"PL Toutain","year":"2004","unstructured":"Toutain, P. L. & Lef\u00e8bvre, H. P. Pharmacokinetics and pharmacokinetic\/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. J. Vet. Pharmacol. Ther. 27, 515\u2013525 (2004).","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"29771_CR15","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"ALP Caforio","year":"2013","unstructured":"Caforio, A. L. P. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 34, 2636\u20132648 (2013).","journal-title":"Eur. Heart J."},{"key":"29771_CR16","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2460\/ajvr.1995.56.12.1620","volume":"56","author":"JN King","year":"1995","unstructured":"King, J. N., Mauron, C. & Kaiser, G. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. Am. J. Vet. Res. 56, 1620\u20131628 (1995).","journal-title":"Am. J. Vet. Res."},{"key":"29771_CR17","first-page":"1087","volume":"292","author":"PL Toutain","year":"2000","unstructured":"Toutain, P. L., Lef\u00e8bvre, H. P. & King, J. N. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic\/pharmacodynamic modeling approach. J. Pharmacol. Exp. Ther. 292, 1087\u20131093 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"29771_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1939-1676.1998.tb02101.x","volume":"12","author":"RL Hamlin","year":"1998","unstructured":"Hamlin, R. L. & Nakayama, T. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. J. Vet. Intern. Med. 12, 93\u201395 (1998).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","volume":"264","author":"F Fyhrquist","year":"2008","unstructured":"Fyhrquist, F. & Saijonmaa, O. Renin-angiotensin system revisited. J. Intern. Med. 264, 224\u2013236 (2008).","journal-title":"J. Intern. Med."},{"key":"29771_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1053\/euhj.1999.1740","volume":"21","author":"E Roig","year":"2000","unstructured":"Roig, E. et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur. Heart J. 21, 53\u201357 (2000).","journal-title":"Eur. Heart J."},{"key":"29771_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jvc.2017.03.001","volume":"19","author":"MK Ames","year":"2017","unstructured":"Ames, M. K., Atkins, C. E., Eriksson, A. & Hess, A. M. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease. J. Vet. Cardiol. 19, 218\u2013227 (2017).","journal-title":"J. Vet. Cardiol."},{"key":"29771_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijcard.2005.02.016","volume":"106","author":"RMA Van De Wal","year":"2006","unstructured":"Van De Wal, R. M. A. et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int. J. Cardiol. 106, 367\u2013372 (2006).","journal-title":"Int. J. Cardiol."},{"key":"29771_CR23","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1210\/endo.131.4.1396304","volume":"131","author":"K Geary","year":"1992","unstructured":"Geary, K., Hunt, M., Peach, M., Gomez, R. & Carey, R. Effects of angiotensin converting enzyme inhibition, sodium depletion, calcium, isoproterenol, and angiotensin II on renin secretion by individual renocortical cells. Endocrinology 131, 1588\u20131594 (1992).","journal-title":"Endocrinology"},{"key":"29771_CR24","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3109\/07420528.2013.807275","volume":"30","author":"J Mochel","year":"2013","unstructured":"Mochel, J. et al. Chronobiology of the renin-angiotensin-aldosterone system in dogs: Relation to blood pressure and renal physiology. Chronobiol. Int. 30, 1144\u20131159 (2013).","journal-title":"Chronobiol. Int."},{"key":"29771_CR25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3109\/07420528.2014.897711","volume":"31","author":"J Mochel","year":"2014","unstructured":"Mochel, J. et al. Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs. Chronobiol. Int. 31, 715\u2013730 (2014).","journal-title":"Chronobiol. Int."},{"key":"29771_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3109\/07420528.2012.709448","volume":"30","author":"RC Hermida","year":"2013","unstructured":"Hermida, R. C. et al. Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol. Int. 30, 280\u2013314 (2013).","journal-title":"Chronobiol. Int."},{"key":"29771_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1939-1676.1996.tb02033.x","volume":"10","author":"RL Hamlin","year":"1996","unstructured":"Hamlin, R. L., Benitz, A. M., Ericsson, G. F., Cifelli, S. & Daurio, C. P. Effects of enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. J. Vet. Intern. Med. 10, 85\u201387 (1996).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1532-950X.1990.tb01178.x","volume":"19","author":"LW Blackford","year":"1990","unstructured":"Blackford, L. W., Golden, A. L., Bright, J. M., Bright, R. M. & Gompf, R. E. Captopril provides sustained hemodynamic benefits in dogs with experimentally induced mitral regurgitation. Vet. Surg. 19, 237\u2013242 (1990).","journal-title":"Vet. Surg."},{"key":"29771_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2460\/ajvr.2003.64.321","volume":"64","author":"SA Brown","year":"2003","unstructured":"Brown, S. A. et al. Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. Am. J. Vet. Res. 64, 321\u2013327 (2003).","journal-title":"Am. J. Vet. Res."},{"key":"29771_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1292\/jvms.60.213","volume":"60","author":"Y Uehara","year":"1998","unstructured":"Uehara, Y. & Takahashi, M. Hemodynamic changes during administration of drugs for mitral regurgitation in dogs. J. Vet. Med. Sci. 60, 213\u2013218 (1998).","journal-title":"J. Vet. Med. Sci."},{"key":"29771_CR31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1939-1676.2009.0455.x","volume":"24","author":"T Ishikawa","year":"2010","unstructured":"Ishikawa, T. et al. The effect of angiotensin-converting enzyme inhibitors of left atrial pressure in dogs with mitral valve regurgitation. J. Vet. Intern. Med. 24, 342\u2013347 (2010).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1292\/jvms.64.385","volume":"64","author":"M Uechi","year":"2002","unstructured":"Uechi, M., Imamoto, S. & Ishikawa, Y. Dose-dependent inhibition of angiotensin converting enzyme by enalapril in cats. J. Vet. Med. Sci. 64, 385\u2013387 (2002).","journal-title":"J. Vet. Med. Sci."},{"key":"29771_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1046\/j.1365-2885.2002.00427.x","volume":"25","author":"JN King","year":"2002","unstructured":"King, J. N., Strehlau, G., Wernsing, J. & Brown, S. A. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats. J. Vet. Pharmacol. Ther. 25, 371\u2013378 (2002).","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"29771_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1939-1676.1995.tb01074.x","volume":"9","author":"D Sisson","year":"1995","unstructured":"Sisson, D. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: Results of the Invasive multicenter prospective veterinary evaluation of enalapril study. The IMPROVE study group. J. Vet. Intern. Med. 9, 234\u2013242 (1995).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR35","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2460\/javma.1998.213.11.1573","volume":"213","author":"S Ettinger","year":"1998","unstructured":"Ettinger, S. et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) study group. J. Am. Vet. Med. Assoc. 213, 1573\u20131577 (1998).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"29771_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1939-1676.2002.tb01610.x","volume":"16","author":"C Kvart","year":"2002","unstructured":"Kvart, C. et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J. Vet. Intern. Med. 16, 80\u201388 (2002).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jvc.2019.12.002","volume":"27","author":"M Borgarelli","year":"2020","unstructured":"Borgarelli, M. et al. DELay of appearance of symptoms of canine degenerative mitral valve disease treated with spironolactone and benazepril: The DELAY study. J. Vet. Cardiol. 27, 34\u201353 (2020).","journal-title":"J. Vet. Cardiol."},{"key":"29771_CR38","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2460\/javma.231.7.1061","volume":"231","author":"CE Atkins","year":"2007","unstructured":"Atkins, C. E. et al. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J. Am. Vet. Med. Assoc. 231, 1061\u20131069 (2007).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"29771_CR39","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1111\/jvim.16236","volume":"35","author":"JL Ward","year":"2021","unstructured":"Ward, J. L., Cou, Y., Yuan, L., Dorman, K. S. & Mochel, J. P. Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease. J. Vet. Intern. Med. 35, 2102\u20132111 (2021).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR40","doi-asserted-by":"publisher","first-page":"e5406","DOI":"10.1371\/journal.pone.0005406","volume":"4","author":"V Esteban","year":"2009","unstructured":"Esteban, V. et al. Angiotensin-(1\u20137) and the G protein-coupled receptor Mas are key players in renal inflammation. PLoS One 4, e5406 (2009).","journal-title":"PLoS One"},{"key":"29771_CR41","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1124\/pr.118.017129","volume":"71","author":"LB Arendse","year":"2019","unstructured":"Arendse, L. B. et al. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol. Rev. 71, 539\u2013570 (2019).","journal-title":"Pharmacol. Rev."},{"key":"29771_CR42","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1111\/jvim.15548","volume":"33","author":"\u00c9 Larouche-Lebel","year":"2019","unstructured":"Larouche-Lebel, \u00c9. et al. Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease. J. Vet. Intern. Med. 33, 1571\u20131584 (2019).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1365-2885.2012.01406.x","volume":"36","author":"JP Mochel","year":"2013","unstructured":"Mochel, J. P. et al. Capturing the dynamics of systemic renin-angiotensin-aldosterone system (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. J. Vet. Pharmacol. Ther. 36, 174\u2013180 (2013).","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"29771_CR44","doi-asserted-by":"publisher","first-page":"33678","DOI":"10.1038\/srep33678","volume":"6","author":"O Domenig","year":"2016","unstructured":"Domenig, O. et al. Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney. Sci. Rep. 6, 33678 (2016).","journal-title":"Sci. Rep."},{"key":"29771_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/jvim.15948","volume":"35","author":"T Huh","year":"2021","unstructured":"Huh, T., Larouche-Lebel, \u00c9., Loughran, K. A. & Oyama, M. A. Effect of angiotensin receptor blockers and angiotensin-converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease. J. Vet. Intern. Med. 35, 33\u201342 (2021).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR46","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/clinchem\/hvaa001","volume":"66","author":"Z Guo","year":"2020","unstructured":"Guo, Z. et al. Measurement of equilibrium angiotensin II in the diagnosis of primary aldosteronism. Clin. Chem. 66, 483\u2013492 (2020).","journal-title":"Clin. Chem."},{"key":"29771_CR47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1373\/clinchem.2017.278705","volume":"64","author":"N Pavo","year":"2018","unstructured":"Pavo, N. et al. Low-and high-renin heart failure phenotypes with clinical implications. Clin. Chem. 64, 597\u2013608 (2018).","journal-title":"Clin. Chem."},{"key":"29771_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1161\/HYPERTENSIONAHA.119.13772","volume":"75","author":"J Burrello","year":"2020","unstructured":"Burrello, J. et al. Renin-angiotensin-aldosterone system triple-A analysis for the screening of primary aldosteronism. Hypertension 75, 163\u2013172 (2020).","journal-title":"Hypertension"},{"key":"29771_CR49","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S2213-2600(20)30418-5","volume":"8","author":"A Zoufaly","year":"2020","unstructured":"Zoufaly, A. et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. 8, 1154\u20131158 (2020).","journal-title":"Lancet Respir. Med."},{"key":"29771_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejps.2018.11.037","volume":"128","author":"JP Mochel","year":"2019","unstructured":"Mochel, J. P. et al. Sacubitril\/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation. Eur. J. Pharm. Sci. 128, 103\u2013111 (2019).","journal-title":"Eur. J. Pharm. Sci."},{"key":"29771_CR51","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/jvp.12017","volume":"35","author":"J Mochel","year":"2012","unstructured":"Mochel, J. & Fink, M. Response to letter from Atkins et al. capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. J. Vet. Pharmacol. Ther. 35, 516\u2013518 (2012).","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"29771_CR52","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/CS20110036","volume":"121","author":"S Bosnyak","year":"2011","unstructured":"Bosnyak, S. et al. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin. Sci. (Lond) 121, 297\u2013303 (2011).","journal-title":"Clin. Sci. (Lond)"},{"key":"29771_CR53","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1939-1676.2011.00735.x","volume":"25","author":"CL Marino","year":"2011","unstructured":"Marino, C. L., Cober, R. E., Iazbik, M. C. & Couto, C. G. White-coat effect on systemic blood pressure in retired racing greyhounds. J. Vet. Intern. Med. 25, 861\u2013865 (2011).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR54","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2460\/ajvr.76.12.1041","volume":"76","author":"MK Ames","year":"2015","unstructured":"Ames, M. K., Atkins, C. E., Lee, S., Lantis, A. C. & zumBrunnen, J. R. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs. Am. J. Vet. Res. 76, 1041\u20131050 (2015).","journal-title":"Am. J. Vet. Res."},{"key":"29771_CR55","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/j.1939-1676.2009.0346.x","volume":"23","author":"M O\u2019Grady","year":"2009","unstructured":"O\u2019Grady, M., O\u2019Sullivan, M., Minors, S. & Horne, R. Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J. Vet. Intern. Med. 23, 977\u2013983 (2009).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR56","doi-asserted-by":"publisher","first-page":"105518","DOI":"10.1016\/j.tvjl.2020.105518","volume":"263","author":"KRS Morgan","year":"2020","unstructured":"Morgan, K. R. S., Monteith, G., Raheb, S., Colpitts, M. & Fonfara, S. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation. Vet. J. 263, 105518 (2020).","journal-title":"Vet. J."},{"key":"29771_CR57","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.2460\/ajvr.69.8.1034","volume":"69","author":"KE Schober","year":"2008","unstructured":"Schober, K. E. et al. Estimation of left ventricular filling pressure by use of Doppler echocardiography in healthy anesthetized dogs subjected to acute volume loading. Am. J. Vet. Res. 69, 1034\u20131049 (2008).","journal-title":"Am. J. Vet. Res."},{"key":"29771_CR58","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1939-1676.2008.0099.x","volume":"22","author":"KE Schober","year":"2008","unstructured":"Schober, K. E. et al. Estimation of left ventricular filling pressure by Doppler echocardiography in dogs with pacing-induced heart failure. J. Vet. Intern. Med. 22, 578\u2013585 (2008).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR59","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1939-1676.2010.0592.x","volume":"24","author":"KE Schober","year":"2010","unstructured":"Schober, K. E. et al. Detection of congestive heart failure in dogs by Doppler echocardiography. J. Vet. Intern. Med. 24, 1358\u20131368 (2010).","journal-title":"J. Vet. Intern. Med."},{"key":"29771_CR60","doi-asserted-by":"publisher","first-page":"20190174","DOI":"10.1098\/rsbl.2019.0174","volume":"15","author":"LG Halsey","year":"2019","unstructured":"Halsey, L. G. The reign of the p-value is over: What alternative analyses could we employ to fill the power vacuum?. Biol. Lett. 15, 20190174 (2019).","journal-title":"Biol. Lett."},{"key":"29771_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nmeth.3288","volume":"12","author":"LG Halsey","year":"2015","unstructured":"Halsey, L. G., Curran-Everett, D., Vowler, S. L. & Drummond, G. B. The fickle P value generates irreproducible results. Nat. Methods 12, 179\u2013185 (2015).","journal-title":"Nat. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29771-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29771-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29771-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:08:26Z","timestamp":1728918506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29771-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["29771"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-29771-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1858200\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"14 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funding for this study was provided by Ceva Sante Animale. Author EG is an employee of Ceva Sante Animale. Authors JLW and JPM have served as consultants for Ceva Sante Animale and have received reimbursement and honoraria for consulting, expert testimony, travel, and service as key opinion leaders (KOLs). Author SS received a stipend from the Iowa State University Summer Scholars Research Program. Authors OD, LY, JSS, VG, and CIS have no relevant competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2684"}}